Latest Lupus erythematosus Stories
ANAHEIM, Calif., July 28, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Canaccord Genuity Growth Conference to be held August 9-11, 2011 at the InterContinental Boston in Boston, MA. Don M.
To view the Social Media Release, click here: http://smr.newswire.ca/en/lupus-canada/first-new-lupus-treatment-in-almost-50-years MARKHAM, ON, July 12, 2011 /PRNewswire/ - Health Canada's recent approval of BENLYSTA(TM) marks the first new treatment available in almost 50 years to the over 1:1000 Canadian men, women and children who are living with Systemic Lupus Erythematosus (SLE) an autoimmune disease with no known cause or cure.
Mayor Michael R. Bloomberg this week presented the S.L.E.
To view the Social Media Release, click here: http://smr.newswire.ca/en/lupus-canada/take-a-step-to-conquer-lupus MARKHAM, ON, May 6 /PRNewswire/ - In the month of May residents in communities across Canada will participate in Lupus Canada's most important public awareness and fundraising event, Walk for Lupus.
HAYWARD, Calif., May 3, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2011.
AWARDS AN ADDITIONAL $3.6 MILLION IN LUPUS RESEARCH, REACHING $5.6 MILLION IN 2010 NEW YORK, April 6, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE, or lupus), a debilitating autoimmune disease.
Scientists have discovered genetic defects that appear to predispose women to a common pregnancy-related medical problem called preeclampsia that can threaten the life of both baby and mother.
The New York City-based S.L.E. Lupus Foundation and its West Coast division Lupus LA welcome the U.S.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug BenlystaÂ® (belimumab), approved today by the U.S. Food and Drug Administration. BenlystaÂ®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
- An imitative word; an onomatopoetic word.